Please assess the completion status of the following clinical trial:

Trial Title: Single Dose PG102 in Patients With Active Psoriatic Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Arthritis that meets Classification of Psoriatic Arthritis (CASPAR) criteria~* Plaque psoriasis for at least 6 months prior to study enrollment~Exclusion Criteria:~* Clinically significant psoriasis flare~* Unstable doses of pain relief medication~* Treatment with systemic corticosteroids other than prednisone ≤ 10 mg/day or equivalent~* Treatment with any biologic therapy~* Treatment with immunosuppressive agents or disease modifying anti-rheumatic drugs (DMARDs) other than methotrexate~* Treatment with lithium, any anti-malarial, chlorambucil, cyclophosphamide or therapies for psoriasis other than low potency topical corticosteroids on intertriginous and groin areas, tar or salicylate preparations on the scalp, and emollients and moisturisers~* Family history of multiple thrombotic events or a personal history of any venous or arterial thrombotic event~* Clinically significant result for anti-cardiolipin, Activated protein C resistance test, Protein C, Free Protein S, Antithrombin III, Factor V Leiden, Prothrombin variant, Homocysteine, Lupus anticoagulant, Prothrombin time, Activated partial thromboplastin time, Fibrinogen, Thrombin time, Factors IX and XI~* Currently smoking ≥ 10 cigarettes per day or equivalent~* Active tuberculosis or other infection~* Current or previous malignancies~* Clinically significant abnormality on physical examination, laboratory testing, vital signs or 12-lead electrocardiogram

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- PG102 0.3 mg/kg (Type: EXPERIMENTAL): Lowest dose PG102
- PG102 1 mg/kg (Type: EXPERIMENTAL): Second dose PG102
- Placebo (phosphate-buffered saline) (Type: PLACEBO_COMPARATOR): Control

Based on this trial design, predict the completion outcome and termination type (if applicable).